Pluri Inc. files S-1 to register 2.23 million shares tied to warrant exercises
The Nasdaq-listed biotech registered common shares issuable to Armistice Capital under warrants from an August 2026 registered direct offering, with an exercise price of $1.65.
Pluri Inc. filed a Form S-1 with the Securities and Exchange Commission on October 6, 2026, covering the resale of up to 2,228,940 common shares issuable upon exercise of warrants held by a single selling shareholder, Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, with the shares deemed beneficially owned by Armistice Capital, LLC as investment manager and Steven Boyd as its Managing Member1. The fund's address is listed as c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.1
The warrants trace to a securities purchase agreement dated August 26, 2026. Under that agreement, Pluri agreed to sell 1,200,000 common shares plus pre-funded warrants for up to 1,028,940 additional shares, with each share priced at $1.50 and each pre-funded warrant priced at $1.499991. Pluri also issued concurrent private-placement common warrants to purchase one share for each share or pre-funded warrant bought, totaling 2,228,940 shares, exercisable starting six months after issuance for a five-year period at $1.65 per share1. Net proceeds to Pluri from that offering were $2,984,798 after fees, intended for corporate development, general purposes and working capital.1
Pluri said it will not receive proceeds from the resale itself but will receive cash proceeds equal to the total exercise price of warrants exercised for cash, or approximately $3,677,751, if all warrants are exercised.1 Pluri's common shares trade on the Nasdaq Capital Market under "PLUR," last closing at $1.04 on October 5, 2026.1 Shares outstanding prior to the offering stood at 12,611,335.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.